サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1389594

生物製剤創薬市場 - 世界および地域別分析（2023年～2033年）

Biologics Drug Discovery Market - A Global and Regional Analysis, 2023-2033
出版日: | 発行: BIS Research | ページ情報: 英文 155 Pages | 納期: 1～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
生物製剤創薬市場 - 世界および地域別分析（2023年～2033年）
出版日: 2023年12月02日
発行: BIS Research
ページ情報: 英文 155 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 目次
概要

生物製剤創薬は、医薬品研究開発における革命的なパラダイムを象徴するものであり、生物学的システム固有の複雑性を活用して、標的を絞った治療的介入を生み出すものです。

従来の低分子医薬品とは異なり、生物学的製剤は、タンパク質、抗体、核酸など、一般的に生体由来の大きく複雑な分子です。このアプローチにより、特に慢性疾患や自己免疫疾患の領域において、疾患に対してより正確でオーダーメイドの対応が可能となります。生物製剤創薬の過程では、対象となる疾患の複雑な生物学を解明し、鍵となる生体分子や経路を特定し、これらの標的を調節することができる治療薬を設計します。このように生物学的な複雑さを微妙に理解することで、従来の薬剤に比べて高い特異性と有効性を示し、多くの場合副作用の少ない治療薬の開発が可能になります。

当レポートでは、世界の生物製剤創薬市場について調査し、市場の概要とともに、手法別、製造タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場：業界の展望

  • 動向：現在および将来の影響評価
  • サプライチェーンの概要
  • 研究開発レビュー
  • 規制状況
  • COVID-19影響分析
  • 市場力学の概要

第2章 用途

  • 用途のセグメンテーション
  • 用途の概要
  • 世界の生物学的創薬市場（手法別）
    • 標的特定/検証
    • ヒットの生成/検証
    • リードの特定
    • リードの最適化
  • 世界の生物学的創薬市場（製造タイプ別）
    • 社内製造
    • 受託製造

第3章 製品

  • 製品のセグメンテーション
  • 製品概要
  • 世界の生物製剤創薬市場（タイプ別）
    • モノクローナル抗体
    • 組換えタンパク質
    • その他

第4章 地域

  • 地域別概要
  • 促進要因と抑制要因
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第5章 市場-競合情勢と企業プロファイル

  • 競合情勢
  • 企業プロファイル
    • AbbVie, Inc.
    • Amgen, Inc.
    • Astellas Pharma, Inc.
    • AstraZeneca, Plc
    • Bayer AG
    • Bicon Ltd.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Eli Lily and Company
    • F.Hoffmann-La Roche AG
    • GenScript
    • Gilead Sciences, Inc.
    • GlaxoSmithKline, Plc
    • Johnson and Johnson
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk
    • Pfizer
    • Sanofi
    • Teva Pharmaceutical Industries, Ltd.
目次
Product Code: BHP0493SB

“Advancements in Biologics Drug Discovery Propel Market Growth.”

Biologics drug discovery represents a revolutionary paradigm in pharmaceutical research and development, leveraging the inherent complexities of biological systems to create targeted therapeutic interventions. Unlike traditional small-molecule drugs, biologics are large, complex molecules typically derived from living organisms, such as proteins, antibodies, or nucleic acids. This approach allows for a more precise and tailored response to diseases, particularly in the realm of chronic conditions and autoimmune disorders. The process of biologics drug discovery involves unraveling the intricate biology of the targeted disease, identifying key biomolecules or pathways, and designing therapeutic agents that can modulate these targets. This nuanced understanding of the biological intricacies enables the development of therapies that exhibit higher specificity, efficacy, and often fewer side effects compared to conventional drugs.

  • The report highlights the transformative impact of biologic therapies on individuals suffering from chronic inflammatory diseases, showcasing how these treatments have not only reduced dependency on health and welfare systems but also improved patients' physical function, enabling them to live more independently.
  • The report delves into various factors influencing the industry, including recent trends, technological advancements, and regulatory aspects. It outlines the market's segmentation based on product, method, manufacture, and geographical regions.
  • The report strategically segments the global biologics drug discovery market based on the phase of discovery, manufacturing type, and product type.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent companies in this market are:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca, Plc
  • Bayer AG
  • Bicon Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lily and Company
  • F.Hoffmann-La Roche AG
  • GenScript
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Plc
  • Johnson and Johnson
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries, Ltd.

Key Questions Answered:

  • What are the major market drivers, challenges, and opportunities in the global biologics drug discovery market and their case studies?
  • How the biologics drug discovery market evolve and what did is its scope in the future?
  • What is the market share of the leading segments and sub-segments of the global biologics drug discovery market in 2023 and 2033?
  • How will each segment of the global biologics drug discovery market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2033?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period between 2023 and 2033?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What will be the growth rate of the outsourced manufacturing segment during the forecast period?

Table of Contents

1. Markets: Industry Outlook

  • 1.1. Trends: Current and Future Impact Assessment
    • 1.1.1. Usage of AI/ML to Accelerate Drug Development
    • 1.1.2. Growing Emphasis on Developing Biosimilars and Biobetters
    • 1.1.3. Shift Towards Targeted and Precision Medicine
  • 1.2. Supply Chain Overview
    • 1.2.1. Value Chain Analysis
  • 1.3. R&D Review
    • 1.3.1. Patent Filing Trend by Country, by Company
  • 1.4. Regulatory Landscape
  • 1.5. Impact Analysis COVID-19
  • 1.6. Market Dynamics Overview
    • 1.6.1. Market Drivers
    • 1.6.2. Market Restraints
    • 1.6.3. Market Opportunities

2. Application

  • 2.1. Application Segmentation
  • 2.2. Application Summary
  • 2.3. Global Biological Drug Discovery Market (by Method)
    • 2.3.1. Target Identification/ validation
    • 2.3.2. Hit Generation/ Validation
    • 2.3.3. Lead Identification
    • 2.3.4. Lead Optimization
  • 2.4. Global Biological Drug Discovery Market (by Manufacture Type)
    • 2.4.1. In-House Manufacturing
    • 2.4.2. Outsourced Manufacturing

3. Product

  • 3.1. Product Segmentation
  • 3.2. Product Summary
  • 3.3. Global Biologics Drug Discovery Market (by Type)
    • 3.3.1. Monoclonal Antibodies
      • 3.3.1.1. Global Monoclonal Antibodies by Method
        • 3.3.1.1.1. Target Identification/ Validation
          • 3.3.1.1.1.1. Functional Genomics/Proteomics
          • 3.3.1.1.1.2. Cell-based Assay
          • 3.3.1.1.1.3. CRISPR/Knockout Studies/Cas9
          • 3.3.1.1.1.4. Animal/Disease Based Models
          • 3.3.1.1.1.5. Computational/in-Silico/Bioinformatics
        • 3.3.1.1.2. Hit Generation/ Validation
          • 3.3.1.1.2.1. mAb Sequencing
          • 3.3.1.1.2.2. Hybridoma Screening
          • 3.3.1.1.2.3. Customized Synthetic Library Screening
          • 3.3.1.1.2.4. Phase Display Screening
          • 3.3.1.1.2.5. High-Throughput Screening
          • 3.3.1.1.2.6. Others
        • 3.3.1.1.3. Lead Identification
          • 3.3.1.1.3.1. Phase Display
          • 3.3.1.1.3.2. ELISA/ADCC & CDC Assay
          • 3.3.1.1.3.3. Array-Based Screening
          • 3.3.1.1.3.4. Hybridoma Screening and Humanization
          • 3.3.1.1.3.5. Bioanalytical Analysis
          • 3.3.1.1.3.6. Others Assays
        • 3.3.1.1.4. Lead Optimization
          • 3.3.1.1.4.1. Humanization
          • 3.3.1.1.4.2. Affinity Analysis
          • 3.3.1.1.4.3. Protein Engineering
          • 3.3.1.1.4.4. In-Vitro/In-Vivo efficacy Assays
          • 3.3.1.1.4.5. Others
    • 3.3.2. Recombinant Proteins
      • 3.3.2.1. Global Protein Recombinant by Method
        • 3.3.2.1.1. Target Identification/ Validation
          • 3.3.2.1.1.1. Functional Genomics/Proteomics
          • 3.3.2.1.1.2. Cell-based Assay
          • 3.3.2.1.1.3. CRISPR/Knockout Studies/Cas9
          • 3.3.2.1.1.4. Animal/Disease Based Models
          • 3.3.2.1.1.5. Computational/in-Silico/Bioinformatics
        • 3.3.2.1.2. Hit Generation/ Validation
          • 3.3.2.1.2.1. mAb Sequencing
          • 3.3.2.1.2.2. Hybridoma Screening
          • 3.3.2.1.2.3. Customized Synthetic Library Screening
          • 3.3.2.1.2.4. Phase Display Screening
          • 3.3.2.1.2.5. High-Throughput Screening
          • 3.3.2.1.2.6. Others
        • 3.3.2.1.3. Lead Identification
          • 3.3.2.1.3.1. Phase Display
          • 3.3.2.1.3.2. ELISA/ADCC & CDC Assay
          • 3.3.2.1.3.3. Array-Based Screening
          • 3.3.2.1.3.4. Hybridoma Screening and Humanization
          • 3.3.2.1.3.5. Bioanalytical Analysis
          • 3.3.2.1.3.6. Others Assays
        • 3.3.2.1.4. Lead Optimization
          • 3.3.2.1.4.1. Humanization
          • 3.3.2.1.4.2. Affinity Analysis
          • 3.3.2.1.4.3. Protein Engineering
          • 3.3.2.1.4.4. In-Vitro/In-Vivo efficacy Assays
          • 3.3.2.1.4.5. Others
    • 3.3.3. Other Biologics

4. Region

  • 4.1. Regional Summary
    • Table: Biologics Drug Discovery Market, By Region, ($ Million), 2022-2033
  • 4.2. Drivers and Restraints
  • 4.3. North America
    • Key Market Participants in North America
    • Business Drivers
    • Business Challenges
    • 4.3.1. Application
      • Table: North America Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.3.2. Product
      • Table: North America Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.3.3. North America (by Country)
      • 4.2.4.1. U.S.
        • Table: U.S. Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.2.4.2. Canada
        • Table: Canada Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.3. Europe
    • 4.3.1. Key Market Participants in Europe
    • 4.3.2. Business Drivers
    • 4.3.3. Business Challenges
    • 4.3.4. Application
      • Table: Europe Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.3.3. Product
      • Table: Europe Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.3.4. Europe (by Country)
      • 4.3.4.1. France
        • Table: France Biologics Drug Discovery Market, By Manufacture Tyoe ($ Million), 2022-2033
      • 4.3.4.2. Germany
        • Table: Germany Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.3. U.K.
        • Table: U.K. Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.4. Switzerland
        • Table: Swizterland Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.5. Rest-of-Europe
        • Table: Rest-of Europe Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.4. Asia-Pacific
    • 4.4.1. Key Market Participants in Asia-Pacific
    • 4.4.2. Business Drivers
    • 4.4.3. Business Challenges
    • 4.4.2. Application
      • Table: Asia-Pacific Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.4.3. Product
      • Table: Asia-Pacific Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.4.4. Asia-Pacific (by Country)
      • 4.4.4.1. China
        • Table: China Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.2. India
        • Table: India Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.3. Japan
        • Table: Japan Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.4. Australia
        • Table: Australia Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.5. Rest-of-Asia-Pacific
        • Table: Rest-of-Asia-Pacific Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.5. Rest-of-the-World
    • 4.5.1. Key Market Participants in Rest-of-the-World
    • 4.5.2. Business Drivers
    • 4.5.3. Business Challenges
    • 4.5.4. Application
      • Table: Rest-of-the-World Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.5.4. Product
      • Table: Rest-of-the-World Biologics Drug Discovery Market, By Type ($ Million), 2022-2033

5. Markets - Competitive Landscape & Company Profiles

  • 5.1. Competitive Landscape
  • 5.2. Company Profile
    • 5.2.1. AbbVie, Inc.
      • 5.2.1.1. Company Overview
      • 5.2.1.2. Product Portfolio
      • 5.2.1.3. Analyst View
    • 5.2.2. Amgen, Inc.
      • 5.2.2.1. Company Overview
      • 5.2.2.2. Product Portfolio
      • 5.2.2.3. Analyst View
    • 5.2.3. Astellas Pharma, Inc.
      • 5.2.3.1. Company Overview
      • 5.2.3.2. Product Portfolio
      • 5.2.3.3. Analyst View
    • 5.2.4. AstraZeneca, Plc
      • 5.2.4.1. Company Overview
      • 5.2.4.2. Product Portfolio
      • 5.2.4.3. Analyst View
    • 5.2.5. Bayer AG
      • 5.2.5.1. Company Overview
      • 5.2.5.2. Product Portfolio
      • 5.2.5.3. Analyst View
    • 5.2.6. Bicon Ltd.
      • 5.2.6.1. Company Overview
      • 5.2.6.2. Product Portfolio
      • 5.2.6.3. Analyst View
    • 5.2.7. Boehringer Ingelheim GmbH
      • 5.2.7.1. Company Overview
      • 5.2.7.2. Product Portfolio
      • 5.2.7.3. Analyst View
    • 5.2.8. Bristol-Myers Squibb Company
      • 5.2.8.1. Company Overview
      • 5.2.8.2. Product Portfolio
      • 5.2.8.3. Analyst View
    • 5.2.9. Eli Lily and Company
      • 5.2.9.1. Company Overview
      • 5.2.9.2. Product Portfolio
      • 5.2.9.3. Analyst View
    • 5.2.10. F.Hoffmann-La Roche AG
      • 5.2.10.1. Company Overview
      • 5.2.10.2. Product Portfolio
      • 5.2.10.3. Analyst View
    • 5.2.11. GenScript
      • 5.2.11.1. Company Overview
      • 5.2.11.2. Product Portfolio
      • 5.2.11.3. Analyst View
    • 5.2.12. Gilead Sciences, Inc.
      • 5.2.12.1. Company Overview
      • 5.2.12.2. Product Portfolio
      • 5.2.12.3. Analyst View
    • 5.2.13. GlaxoSmithKline, Plc
      • 5.2.13.1. Company Overview
      • 5.2.13.2. Product Potfolio
      • 5.2.13.3. Analyst View
    • 5.2.14. Johnson and Johnson
      • 5.2.14.1. Company Overview
      • 5.2.14.2. Product Potfolio
      • 5.2.14.4. Analyst View
    • 5.2.15. Laboratory Corporation of America Holdings
      • 5.2.15.1. Company Overview
      • 5.2.15.2. Product Potfolio
      • 5.2.15.3. Analyst View
    • 5.2.16. Merck KGaA
      • 5.2.16.1. Company Overview
      • 5.2.16.2. Product Potfolio
      • 5.2.16.4. Analyst View
    • 5.2.17. Novartis AG
      • 5.2.17.1. Company Overview
      • 5.2.17.2. Product Potfolio
      • 5.2.17.3. Analyst View
    • 5.2.18. Novo Nordisk
      • 5.2.18.1. Company Overview
      • 5.2.18.2. Product Potfolio
      • 5.2.18.3. Analyst View
    • 5.2.19. Pfizer
      • 5.2.19.1. Company Overview
      • 5.2.19.2. Product Potfolio
      • 5.2.19.3. Analyst View
    • 5.2.20. Sanofi
      • 5.2.20.1. Company Overview
      • 5.2.20.2. Product Potfolio
      • 5.2.20.3. Analyst View
    • 5.2.21. Teva Pharmaceutical Industries, Ltd.
      • 5.2.21.1. Company Overview
      • 5.2.21.2. Product Potfolio
      • 5.2.21.3. Analyst View